Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ST-101 (Stratus Therapeutics)
- Development stage
- Preclinical
- Lead developer
- Stratus Therapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
ST-101 is an allogeneic, off-the-shelf hematopoietic stem cell (HSC) therapy developed by Stratus Therapeutics (formerly Garuda Therapeutics) for the treatment of blood and immune disorders. The therapy is generated using the proprietary Stratus Prime platform, which employs the targeted activation of the **PIEZO1 mechanosensitive ion channel** to differentiate human pluripotent stem cells (hPSCs) into transgene-free, long-term reconstituting HSCs and hematopoietic progenitor cells (HPCs). ST-101 is designed to provide a universal, on-demand graft that eliminates the need for human leukocyte antigen (HLA) donor matching. By removing T-cells during the manufacturing process, the therapy aims to achieve durable hematopoietic restoration and rapid immune reconstitution while significantly reducing the risk of graft-versus-host disease (GvHD). Its lead indications include transfusion-dependent beta-thalassemia and bone marrow failure syndromes.
- Other names
- Prime HSCsPrime HPCs
Beyond the preview
Go deeper on ST-101 (Stratus Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ST-101 (Stratus Therapeutics).